Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Daily Top 10 COVID-19 papers

DEU | ENG | ESP | FRA | ITA | POR | TUR | VNM


  Gynecology

  Free Subscription


Articles published in Int J Cancer

Retrieve available abstracts of 223 articles:
HTML format



Single Articles


    May 2020
  1. LI Y, Hendryx MS, Xun P, He K, et al
    Physical activity and risk of bladder cancer among postmenopausal women.
    Int J Cancer. 2020 May 10. doi: 10.1002/ijc.33042.
    PubMed     Abstract available


    April 2020
  2. OMIYALE W, Allen NE, Sweetland S
    Body size, body composition and endometrial cancer risk among postmenopausal women in UK Biobank.
    Int J Cancer. 2020 Apr 27. doi: 10.1002/ijc.33023.
    PubMed     Abstract available


  3. JIANG YT, Gong TT, Zhang JY, Li XQ, et al
    Infertility and ovarian cancer risk: evidence from nine prospective cohort studies.
    Int J Cancer. 2020 Apr 14. doi: 10.1002/ijc.33012.
    PubMed     Abstract available


  4. TIN ST, Reeves GK, Key TJ
    Body size and composition, physical activity and sedentary time in relation to endogenous hormones in pre- and post-menopausal women: findings from the UK Biobank.
    Int J Cancer. 2020 Apr 14. doi: 10.1002/ijc.33010.
    PubMed     Abstract available


  5. JUNG M, Gao J, Cheung L, Bongers A, et al
    ABCC4/MRP4 contributes to the aggressiveness of Myc-associated epithelial ovarian cancer.
    Int J Cancer. 2020 Apr 10. doi: 10.1002/ijc.33005.
    PubMed     Abstract available


  6. IDAHL A, Cornet CL, Maldonado SG, Waterboer T, et al
    Serologic markers of Chlamydia trachomatis and other sexually transmitted infections and subsequent ovarian cancer risk: Results from the EPIC cohort.
    Int J Cancer. 2020 Apr 3. doi: 10.1002/ijc.32999.
    PubMed     Abstract available


  7. YANG H, Ye S, Goswami S, Li T, et al
    Highly immunosuppressive HLADR(hi) regulatory T cells are associated with unfavorable outcomes in cervical squamous cell carcinoma.
    Int J Cancer. 2020;146:1993-2006.
    PubMed     Abstract available


    March 2020
  8. GONG Y, Yang J, Wang Y, Xue L, et al
    Metabolic Factors Contribute to T-cell Inhibition in the Ovarian Cancer Ascites.
    Int J Cancer. 2020 Mar 24. doi: 10.1002/ijc.32990.
    PubMed     Abstract available


  9. SINGH A, Gupta S, Badarukhiya JA, Sachan M, et al
    "Detection of aberrant methylation of HOXA9 and HIC1 through multiplex MethyLight assay in serum DNA for the early detection of epithelial ovarian cancer".
    Int J Cancer. 2020 Mar 19. doi: 10.1002/ijc.32984.
    PubMed     Abstract available


  10. DASHTI SG, Viallon V, Simpson JA, Karahalios A, et al
    Explaining the link between adiposity and colorectal cancer risk in men and postmenopausal women in the UK Biobank: a sequential causal mediation analysis.
    Int J Cancer. 2020 Mar 17. doi: 10.1002/ijc.32980.
    PubMed     Abstract available


  11. ESSERS PBM, van der Heijden M, Vossen D, de Roest RH, et al
    Ovarian cancer derived copy number alterations signatures are prognostic in chemoradiotherapy treated head and neck squamous cell carcinoma.
    Int J Cancer. 2020 Mar 13. doi: 10.1002/ijc.32962.
    PubMed     Abstract available


  12. KATO M, Onoyama I, Yoshida S, Cui L, et al
    Dual specificity phosphatase 6 plays a critical role in the maintenance of a cancer stem-like cell phenotype in human endometrial cancer.
    Int J Cancer. 2020 Mar 11. doi: 10.1002/ijc.32965.
    PubMed     Abstract available


  13. PILLERON S, Cabasag CJ, Ferlay J, Bray F, et al
    Cervical cancer burden in Latin America and the Caribbean: Where are we?
    Int J Cancer. 2020 Mar 9. doi: 10.1002/ijc.32956.
    PubMed     Abstract available


  14. HAMMER A, Demarco M, Campos N, Befano B, et al
    Study of the Risks of CIN3+ detection following multiple rounds of HPV testing: Results of the 15-year cervical cancer screening experience at Kaiser Permanente Northern California.
    Int J Cancer. 2020 Mar 6. doi: 10.1002/ijc.32950.
    PubMed     Abstract available


    February 2020
  15. ZHONG GC, Peng Y, Wang K, Wan L, et al
    Magnesium intake and primary liver cancer incidence and mortality in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.
    Int J Cancer. 2020 Feb 27. doi: 10.1002/ijc.32939.
    PubMed     Abstract available


  16. BENVENUTO G, Todeschini P, Paracchini L, Calura E, et al
    Expression profiles of PRKG1, SDF2L1 and PPP1R12A are predictive and prognostic factors for therapy response and survival in high-grade serous ovarian cancer.
    Int J Cancer. 2020 Feb 25. doi: 10.1002/ijc.32935.
    PubMed     Abstract available


  17. JOHN EM, Phipps AI, Hines LM, Koo J, et al
    Menstrual and reproductive characteristics and breast cancer risk by hormone receptor status and race/ethnicity: The Breast Cancer Etiology in Minorities (BEM) Study.
    Int J Cancer. 2020 Feb 16. doi: 10.1002/ijc.32923.
    PubMed     Abstract available


  18. KOTSOPOULOS J, Narod SA
    Prophylactic salpingectomy for the prevention of ovarian cancer; who should we target?
    Int J Cancer. 2020 Feb 9. doi: 10.1002/ijc.32916.
    PubMed     Abstract available


  19. REIJNEN C, Kusters-Vandevelde HVN, Ligtenberg MJL, Bulten J, et al
    Molecular profiling identifies synchronous endometrial and ovarian cancers as metastatic endometrial cancer with favorable clinical outcome.
    Int J Cancer. 2020 Feb 5. doi: 10.1002/ijc.32907.
    PubMed     Abstract available


  20. HECK JE, Lee PC, Wu CK, Tsai HY, et al
    Gestational risk factors and childhood cancers: a cohort study in Taiwan.
    Int J Cancer. 2020 Feb 5. doi: 10.1002/ijc.32905.
    PubMed     Abstract available


  21. LIPPENS L, Van Bockstal M, De Jaeghere EA, Tummers P, et al
    Immunologic impact of chemoradiation in cervical cancer and how immune cell infiltration could lead towards personalized treatment.
    Int J Cancer. 2020 Feb 3. doi: 10.1002/ijc.32893.
    PubMed     Abstract available


  22. FORTNER RT, Husing A, Dossus L, Tjonneland A, et al
    Theoretical potential for endometrial cancer prevention through primary risk factor modification: Estimates from the EPIC cohort.
    Int J Cancer. 2020 Feb 3. doi: 10.1002/ijc.32901.
    PubMed     Abstract available


  23. MELIN J, Madanat-Harjuoja L, Hirvonen E, Seppa K, et al
    Use of fertility drugs in early-onset female cancer survivors-A Finnish register-based study on 8,929 survivors.
    Int J Cancer. 2020;146:829-838.
    PubMed     Abstract available


  24. CLEVELAND AA, Gargano JW, Park IU, Griffin MR, et al
    Cervical adenocarcinoma in situ: Human papillomavirus types and incidence trends in five states, 2008-2015.
    Int J Cancer. 2020;146:810-818.
    PubMed     Abstract available


    January 2020
  25. MAYO-DE-LAS-CASAS C, Velasco A, Sanchez D, Martinez-Bueno A, et al
    Detection of somatic mutations in peritoneal lavages and plasma of endometrial cancer patients: a proof-of-concept study.
    Int J Cancer. 2020 Jan 17. doi: 10.1002/ijc.32872.
    PubMed     Abstract available


  26. AMITAY EL, Carr PR, Jansen L, Alwers E, et al
    Postmenopausal hormone replacement therapy and colorectal cancer risk by molecular subtypes and pathways.
    Int J Cancer. 2020 Jan 14. doi: 10.1002/ijc.32868.
    PubMed     Abstract available


  27. HANNIBAL CG, Frederiksen K, Vang R, Kurman RJ, et al
    Risk of specific types of ovarian cancer after borderline ovarian tumors in Denmark: a nationwide-based study.
    Int J Cancer. 2020 Jan 12. doi: 10.1002/ijc.32864.
    PubMed     Abstract available


  28. YOSHIHARA M, Kajiyama H, Yokoi A, Sugiyama M, et al
    Ovarian cancer-associated mesothelial cells induce acquired platinum-resistance in peritoneal metastasis via the FN1/Akt signaling pathway.
    Int J Cancer. 2020 Jan 6. doi: 10.1002/ijc.32854.
    PubMed     Abstract available


    December 2019
  29. GABY S, Eva E, Andreas W, Wilhelm O, et al
    Reducing Overtreatment Associated with Overdiagnosis in Cervical Cancer Screening - A Model-based Benefit-Harm Analysis for Austria.
    Int J Cancer. 2019 Dec 24. doi: 10.1002/ijc.32849.
    PubMed     Abstract available


  30. RAMRAJ SK, Elayapillai SP, Pelikan RC, Zhao YD, et al
    Novel Ovarian Cancer Maintenance Therapy Targeted at Mortalin and Mutant p53.
    Int J Cancer. 2019 Dec 17. doi: 10.1002/ijc.32830.
    PubMed     Abstract available


  31. LANDY R, Sasieni PD, Mathews C, Wiggins CL, et al
    Impact of screening on cervical cancer incidence. A population-based case-control study in the United States.
    Int J Cancer. 2019 Dec 13. doi: 10.1002/ijc.32826.
    PubMed     Abstract available


  32. WOLF D, Fiegl H, Zeimet AG, Wieser V, et al
    High RIG-I expression in ovarian cancer associates with an immune-escape signature and poor clinical outcome.
    Int J Cancer. 2019 Dec 4. doi: 10.1002/ijc.32818.
    PubMed     Abstract available


  33. ELFSTROM KM, Sundstrom K, Andersson S, Bzhalava Z, et al
    Increasing participation in cervical screening by targeting long-term nonattenders: Randomized health services study.
    Int J Cancer. 2019;145:3033-3039.
    PubMed     Abstract available


    November 2019
  34. NOH H, Charvat H, Freisling H, Olafsdottir GH, et al
    Cumulative exposure to premenopausal obesity and risk of postmenopausal cancer: A population-based study in Icelandic women.
    Int J Cancer. 2019 Nov 21. doi: 10.1002/ijc.32805.
    PubMed     Abstract available


  35. COSPER PF, McNair C, Gonzalez I, Wong N, et al
    Decreased Local Immune Response and Retained HPV Gene Expression during Chemoradiotherapy are Associated with Treatment Resistance and Death from Cervical Cancer.
    Int J Cancer. 2019 Nov 15. doi: 10.1002/ijc.32793.
    PubMed     Abstract available


  36. YANG Y, Meng YL, Duan SM, Zhan SB, et al
    REBACIN(R) as a noninvasive clinical intervention for high-risk human papillomavirus persistent infection.
    Int J Cancer. 2019;145:2712-2719.
    PubMed     Abstract available


  37. ORUMAA M, Leinonen MK, Campbell S, Moller B, et al
    Recent increase in incidence of cervical precancerous lesions in Norway: Nationwide study from 1992 to 2016.
    Int J Cancer. 2019;145:2629-2638.
    PubMed     Abstract available


  38. MYERS AP, Konstantinopoulos PA, Barry WT, Luo W, et al
    Phase II, 2-Stage, 2-Arm, PIK3CA Mutation Stratified Trial of MK-2206 in Recurrent Endometrial Cancer.
    Int J Cancer. 2019 Nov 12. doi: 10.1002/ijc.32783.
    PubMed     Abstract available


  39. WANG T, Townsend MK, Simmons V, Terry KL, et al
    Pre- and Post- Diagnosis Smoking and Survival Following Diagnosis with Ovarian Cancer.
    Int J Cancer. 2019 Nov 6. doi: 10.1002/ijc.32773.
    PubMed     Abstract available


  40. SOKOLENKO AP, Bizin IV, Preobrazhenskaya EV, Gorodnova TV, et al
    Molecular Profiles of BRCA1-Associated Ovarian Cancer Treated by Platinum-Based Therapy: Analysis of Primary, Residual and Relapsed Tumours.
    Int J Cancer. 2019 Nov 6. doi: 10.1002/ijc.32776.
    PubMed     Abstract available


    October 2019
  41. KRATZER TB, Weinstein SJ, Albanes D, Mondul AM, et al
    Vitamin D Binding Protein and Risk of Renal Cell Carcinoma in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO).
    Int J Cancer. 2019 Oct 29. doi: 10.1002/ijc.32758.
    PubMed     Abstract available


  42. FOKOM DOMGUE J, Futuh B, Ngalla C, Kakute P, et al
    Feasibility of a Community-based Cervical Cancer Screening with 'Test and Treat' strategy using self-sample for an HPV Test: Experience from rural Cameroon, Africa.
    Int J Cancer. 2019 Oct 21. doi: 10.1002/ijc.32746.
    PubMed     Abstract available


  43. FELIX AS, McLaughlin EM, Caan BJ, Cohn DE, et al
    Guideline-concordant endometrial cancer treatment and survival in the Women's Health Initiative Life and Longevity After Cancer study.
    Int J Cancer. 2019 Oct 16. doi: 10.1002/ijc.32740.
    PubMed     Abstract available


  44. LEE YJ, Kim D, Shim JE, Bae SJ, et al
    Genomic profiling of the residual disease of advanced high-grade serous ovarian cancer after neoadjuvant chemotherapy.
    Int J Cancer. 2019 Oct 11. doi: 10.1002/ijc.32729.
    PubMed     Abstract available


  45. BRAUN JA, Herrmann AL, Blase JI, Frensemeier K, et al
    Effects of the Antifungal Agent Ciclopirox in HPV-Positive Cancer Cells: Repression of Viral E6/E7 Oncogene Expression and Induction of Senescence and Apoptosis.
    Int J Cancer. 2019 Oct 11. doi: 10.1002/ijc.32709.
    PubMed     Abstract available


  46. SIMIN J, Rulla MT, Callens S, Engstrand L, et al
    Menopausal hormone therapy treatment options and ovarian cancer risk: A Swedish prospective population-based matched-cohort study.
    Int J Cancer. 2019 Oct 4. doi: 10.1002/ijc.32706.
    PubMed     Abstract available


  47. QIU JJ, Lin XJ, Tang XY, Zheng TT, et al
    Long Noncoding RNA TC0101441 induces epithelial-mesenchymal transition in epithelial ovarian cancer metastasis by downregulating KiSS1.
    Int J Cancer. 2019 Oct 2. doi: 10.1002/ijc.32692.
    PubMed     Abstract available


    September 2019
  48. SADRI NAHAND J, Moghoofei M, Salmaninejad A, Bahmanpour Z, et al
    Pathogenic role of exosomes and microRNAs in HPV-mediated inflammation and cervical cancer: A review.
    Int J Cancer. 2019 Sep 30. doi: 10.1002/ijc.32688.
    PubMed     Abstract available


  49. REIJNEN C, van der Putten LJM, Bulten J, Snijders MPLM, et al
    Mutational analysis of cervical cytology improves diagnosis of endometrial cancer: a prospective multicentre cohort study.
    Int J Cancer. 2019 Sep 15. doi: 10.1002/ijc.32686.
    PubMed     Abstract available


  50. LINK T, Passek S, Wimberger P, Frank K, et al
    Serum calretinin as an independent predictor for platinum resistance and prognosis in ovarian cancer.
    Int J Cancer. 2019 Sep 11. doi: 10.1002/ijc.32676.
    PubMed     Abstract available


  51. LYU T, Jiang Y, Jia N, Che X, et al
    SMYD3 promotes implant metastasis of ovarian cancer via H3K4 trimethylation of integrin promoters.
    Int J Cancer. 2019 Sep 10. doi: 10.1002/ijc.32673.
    PubMed     Abstract available


  52. KONG Y, Wang Z, Huang M, Zhou Z, et al
    CUL7 promotes cancer cell survival through promoting Caspase-8 ubiquitination.
    Int J Cancer. 2019;145:1371-1381.
    PubMed     Abstract available


  53. YI T, Feng Y, Sundaram R, Tie Y, et al
    Antitumor efficacy of PARP inhibitors in homologous recombination deficient carcinomas.
    Int J Cancer. 2019;145:1209-1220.
    PubMed     Abstract available


    August 2019
  54. MANICHAIKUL A, Peres LC, Wang XQ, Barnard ME, et al
    Identification of novel epithelial ovarian cancer loci in Women of African Ancestry.
    Int J Cancer. 2019 Aug 30. doi: 10.1002/ijc.32653.
    PubMed     Abstract available


  55. RICE MS, Poole EM, Willett WC, Tworoger SS, et al
    Adult Dietary Fat Intake and Ovarian Cancer Risk.
    Int J Cancer. 2019 Aug 23. doi: 10.1002/ijc.32635.
    PubMed     Abstract available


  56. VINK FJ, Meijer CJLM, Clifford GM, Poljak M, et al
    FAM19A4/miR124-2 methylation in invasive cervical cancer: A retrospective cross-sectional worldwide study.
    Int J Cancer. 2019 Aug 7. doi: 10.1002/ijc.32614.
    PubMed     Abstract available


  57. RAY-COQUARD I, Cibula D, Mirza MR, Reuss A, et al
    Final results from GCIG/ENGOT/AGO-OVAR 12, a randomised placebo-controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer.
    Int J Cancer. 2019 Aug 5. doi: 10.1002/ijc.32606.
    PubMed     Abstract available


  58. RIGHOLT CH, Bozat-Emre S, Mahmud SM
    Effectiveness of school-based and high-risk human papillomavirus vaccination programs against cervical dysplasia in Manitoba, Canada.
    Int J Cancer. 2019;145:671-677.
    PubMed     Abstract available


    July 2019
  59. TAWE L, MacDuffie E, Narasimhamurthy M, Wang Q, et al
    Human Papillomavirus (HPV) Genotypes in Women with Invasive Cervical Cancer with and without Human Immunodeficiency Virus (HIV) Infection in Botswana.
    Int J Cancer. 2019 Jul 20. doi: 10.1002/ijc.32581.
    PubMed     Abstract available


  60. RAAB M, Kobayashi NF, Becker S, Kurunci-Csacsko E, et al
    Boosting the apoptotic response of high grade serous ovarian cancers with CCNE1-amplification to paclitaxel in vitro by targeting APC/C and the pro-survival protein MCL-1.
    Int J Cancer. 2019 Jul 8. doi: 10.1002/ijc.32559.
    PubMed     Abstract available


  61. ZHU Q, Zhang J, Chen Y, Hu Q, et al
    Whole-Exome Sequencing Of Ovarian Cancer Families Uncovers Putative Predisposition Genes.
    Int J Cancer. 2019 Jul 2. doi: 10.1002/ijc.32545.
    PubMed     Abstract available


  62. BERTOLI HK, Rasmussen CL, Sand FL, Albieri V, et al
    Human papillomavirus and p16 in squamous cell carcinoma and intraepithelial neoplasia of the vagina.
    Int J Cancer. 2019;145:78-86.
    PubMed     Abstract available


    June 2019
  63. COLDMAN AJ, van Niekerk D, Krajden M, Smith LW, et al
    Disease Detection at the 48 Month Exit Round of the HPV FOCAL Cervical Cancer Screening Trial in Women Per-Protocol Eligible for Routine Screening.
    Int J Cancer. 2019 Jun 27. doi: 10.1002/ijc.32524.
    PubMed     Abstract available


  64. ROHNER E, Butikofer L, Schmidlin K, Sengayi M, et al
    Cervical cancer risk in women living with HIV across four continents: A multicohort study.
    Int J Cancer. 2019 Jun 19. doi: 10.1002/ijc.32260.
    PubMed     Abstract available


  65. GRUNDY A, Ho V, Abrahamowicz M, Parent ME, et al
    Lifetime recreational moderate-to-vigorous physical activity and ovarian cancer risk: a case-control study.
    Int J Cancer. 2019 Jun 14. doi: 10.1002/ijc.32513.
    PubMed     Abstract available


  66. COSTAS L, Frias-Gomez J, Guardiola M, Benavente Y, et al
    New perspectives on screening and early detection of endometrial cancer.
    Int J Cancer. 2019 Jun 14. doi: 10.1002/ijc.32514.
    PubMed     Abstract available


  67. DASHTI SG, Simpson JA, Karahalios A, Viallon V, et al
    Adiposity and estrogen receptor-positive, postmenopausal breast cancer risk: quantification of the mediating effects of fasting insulin and free estradiol.
    Int J Cancer. 2019 Jun 12. doi: 10.1002/ijc.32504.
    PubMed     Abstract available


  68. ZENG X, Baba T, Hamanishi J, Matsumura N, et al
    Phosphorylation of STAT1 serine 727 enhances platinum resistance in uterine serous carcinoma.
    Int J Cancer. 2019 Jun 10. doi: 10.1002/ijc.32501.
    PubMed     Abstract available


  69. TRABERT B, Troisi R, Grotmol T, Ekbom A, et al
    Associations of pregnancy-related factors and birth characteristics with risk of endometrial cancer: a Nordic population-based case-control study.
    Int J Cancer. 2019 Jun 7. doi: 10.1002/ijc.32494.
    PubMed     Abstract available


  70. MPUNGA T, Umulisa MC, Tenet V, Rugwizangoga B, et al
    Human papillomavirus genotypes in cervical and other HPV-related anogenital cancer in Rwanda, according to HIV status.
    Int J Cancer. 2019 Jun 7. doi: 10.1002/ijc.32491.
    PubMed     Abstract available


  71. WOESTENBERG PJ, Bogaards JA, King AJ, Leussink S, et al
    Assessment of herd effects among women and heterosexual men after girls-only HPV16/18 vaccination in the Netherlands: A repeated cross-sectional study.
    Int J Cancer. 2019;144:2718-2727.
    PubMed     Abstract available


    May 2019
  72. MORI N, Sawada N, Iwasaki M, Yamaji T, et al
    Circulating sex hormone levels and colorectal cancer risk in Japanese postmenopausal women: The JPHC nested case-control study.
    Int J Cancer. 2019 May 27. doi: 10.1002/ijc.32431.
    PubMed     Abstract available


  73. WANG J, Elfstrom KM, Andrae B, Nordqvist Kleppe S, et al
    Cervical cancer case-control audit: Results from routine evaluation of a nationwide cervical screening programme.
    Int J Cancer. 2019 May 20. doi: 10.1002/ijc.32416.
    PubMed     Abstract available


  74. TIAN W, Bi R, Ren Y, He H, et al
    Screening for hereditary cancers in patients with endometrial cancer reveals a high frequency of germline mutations in cancer predisposition genes.
    Int J Cancer. 2019 May 4. doi: 10.1002/ijc.32389.
    PubMed     Abstract available


  75. KLEIBLOVA P, Stolarova L, Krizova K, Lhota F, et al
    Identification of deleterious germline CHEK2 mutations and their association with breast and ovarian cancer.
    Int J Cancer. 2019 May 3. doi: 10.1002/ijc.32385.
    PubMed     Abstract available


  76. BAO C, Yang R, Pedersen NL, Xu W, et al
    Overweight in midlife and risk of cancer in late life: A nationwide Swedish twin study.
    Int J Cancer. 2019;144:2128-2134.
    PubMed     Abstract available


    April 2019
  77. ASSI N, Rinaldi S, Viallon V, Dashti SG, et al
    Mediation analysis of the alcohol-postmenopausal breast cancer relationship by sex hormones in the EPIC Cohort.
    Int J Cancer. 2019 Apr 10. doi: 10.1002/ijc.32324.
    PubMed     Abstract available


  78. CABASAG CJ, Arnold M, Butler J, Inoue M, et al
    The influence of birth cohort and calendar period on global trends in ovarian cancer incidence.
    Int J Cancer. 2019 Apr 10. doi: 10.1002/ijc.32322.
    PubMed     Abstract available


  79. AMARO-FILHO SM, Gradissimo A, Usyk M, Moreira FCB, et al
    HPV73 a non-vaccine type causes cervical cancer.
    Int J Cancer. 2019 Apr 9. doi: 10.1002/ijc.32315.
    PubMed     Abstract available


    March 2019
  80. NURMI A, Muranen TA, Pelttari LM, Kiiski JI, et al
    Recurrent moderate-risk mutations in Finnish breast and ovarian cancer patients.
    Int J Cancer. 2019 Mar 30. doi: 10.1002/ijc.32309.
    PubMed     Abstract available


  81. TIAN J, Geng Y, Lv D, Li P, et al
    Using plasma cell free DNA to monitor the chemo-radiotherapy course of cervical cancer.
    Int J Cancer. 2019 Mar 28. doi: 10.1002/ijc.32295.
    PubMed     Abstract available


  82. LI H, Zhang W, Niu C, Lin C, et al
    Nuclear orphan receptor NR2F6 confers cisplatin resistance in epithelial ovarian cancer cells by activating the Notch3 signaling pathway.
    Int J Cancer. 2019 Mar 20. doi: 10.1002/ijc.32293.
    PubMed     Abstract available


  83. BALLABIO S, Craparotta I, Paracchini L, Mannarino L, et al
    Multisite analysis of high-grade serous epithelial ovarian cancers identifies genomic regions of focal and recurrent copy number variation in 3p26.2 and 8q24.3.
    Int J Cancer. 2019 Mar 20. doi: 10.1002/ijc.32288.
    PubMed     Abstract available


  84. BONDE J, Bottari F, Parvu V, Pedersen H, et al
    BAYESIAN ANALYSIS OF BASELINE RISK OF CIN2 AND >/=CIN3 BY HPV GENOTYPE IN A EUROPEAN REFERRAL COHORT.
    Int J Cancer. 2019 Mar 20. doi: 10.1002/ijc.32291.
    PubMed     Abstract available


  85. LANDY R, Schiffman M, Sasieni PD, Cheung LC, et al
    Absolute risks of cervical precancer among women who fulfil exiting guidelines based on HPV and cytology cotesting.
    Int J Cancer. 2019 Mar 12. doi: 10.1002/ijc.32268.
    PubMed     Abstract available


    February 2019

  86. Expression of Concern: "Aurora-A induces cell survival and chemoresistance by activation of Akt through a p53-dependent manner in ovarian cancer cells" by Hua Yang, Lili He, Patricia Kruk, Santo V. Nicosia and Jin Q. Cheng.
    Int J Cancer. 2019 Feb 27. doi: 10.1002/ijc.32225.
    PubMed    


  87. HE Y, Gu Z, Zhu Q, Chen M, et al
    CA125 over-release behavior following a 75-gram oral glucose test as a predictive biomarker of multidrug resistance in patients with ovarian cancer.
    Int J Cancer. 2019 Feb 26. doi: 10.1002/ijc.32237.
    PubMed     Abstract available


  88. ARRIAGA ME, Vajdic CM, Canfell K, MacInnis RJ, et al
    The preventable burden of breast cancers for premenopausal and postmenopausal women in Australia: a pooled cohort study.
    Int J Cancer. 2019 Feb 25. doi: 10.1002/ijc.32231.
    PubMed     Abstract available


  89. VAN LEEUWEN RW, Ostrbenk A, Poljak M, van der Zee AGJ, et al
    DNA methylation markers as a triage test for identification of cervical lesions in a high risk human papillomavirus positive screening cohort.
    Int J Cancer. 2019;144:746-754.
    PubMed     Abstract available


    January 2019
  90. BHASKARAN SP, Chandratre K, Gupta H, Zhang L, et al
    Germline variation in BRCA1/2 is highly ethnic-specific: evidence from over 30,000 Chinese hereditary breast and ovarian cancer patients.
    Int J Cancer. 2019 Jan 31. doi: 10.1002/ijc.32176.
    PubMed     Abstract available


  91. LI F, Li H, Zhang L, Li W, et al
    X chromosome-linked long noncoding RNA lnc-XLEC1 regulates c-Myc-dependent cell growth by collaborating with MBP-1 in endometrial cancer.
    Int J Cancer. 2019 Jan 30. doi: 10.1002/ijc.32166.
    PubMed     Abstract available


  92. RIOS P, Bailey HD, Poulalhon C, Valteau-Couanet D, et al
    Parental smoking, maternal alcohol consumption during pregnancy and the risk of neuroblastoma in children. A pooled analysis of the ESCALE and ESTELLE French studies.
    Int J Cancer. 2019 Jan 29. doi: 10.1002/ijc.32161.
    PubMed     Abstract available


  93. KAWAKITA D, Lee YA, Gren LH, Buys SS, et al
    Fiber Intake and the Risk of Head and Neck Cancer in the prostate, lung, colorectal, and ovarian (PLCO) cohort.
    Int J Cancer. 2019 Jan 29. doi: 10.1002/ijc.32162.
    PubMed     Abstract available


  94. TRABERT B, Michels KA, Anderson GL, Brinton LA, et al
    Circulating androgens and postmenopausal ovarian cancer risk in the Women's Health Initiative Observational Study.
    Int J Cancer. 2019 Jan 26. doi: 10.1002/ijc.32157.
    PubMed     Abstract available


  95. FERRERA A, Valladares W, Cabrera Y, de la Luz Hernandez M, et al
    Performance of an HPV 16/18 E6 oncoprotein test for detection of cervical precancer and cancer.
    Int J Cancer. 2019 Jan 26. doi: 10.1002/ijc.32156.
    PubMed     Abstract available


  96. CERVENKA I, Al Rahmoun M, Mahamat Saleh Y, Savoye I, et al
    Postmenopausal hormone use and cutaneous melanoma risk: A French prospective cohort study.
    Int J Cancer. 2019 Jan 22. doi: 10.1002/ijc.32150.
    PubMed     Abstract available


  97. PAN J, Kavanagh K, Cuschieri K, Pollock KG, et al
    Increased risk of HPV-associated genital cancers in men and women as a consequence of pre-invasive disease.
    Int J Cancer. 2019 Jan 16. doi: 10.1002/ijc.32126.
    PubMed     Abstract available


  98. BRANDAO RD, Mensaert K, Lopez-Perolio I, Tserpelis D, et al
    Targeted RNA-seq successfully identifies normal and pathogenic splicing events in breast/ovarian cancer susceptibility and Lynch syndrome genes.
    Int J Cancer. 2019 Jan 8. doi: 10.1002/ijc.32114.
    PubMed     Abstract available


  99. LEEMAN A, Del Pino M, Marimon L, Torne A, et al
    Reliable identification of women with CIN3+ using hrHPV genotyping and methylation markers in a cytology-screened referral population.
    Int J Cancer. 2019;144:160-168.
    PubMed     Abstract available


    December 2018
  100. VAN HELLEMOND IEG, Vriens IJH, Peer PGM, Swinkels ACP, et al
    Efficacy of Anastrozole after Tamoxifen in Early Breast Cancer Patients with Chemotherapy-Induced Ovarian Function Failure.
    Int J Cancer. 2018 Dec 26. doi: 10.1002/ijc.32093.
    PubMed     Abstract available


  101. FORTNER RT, Poole EM, Wentzensen NA, Trabert B, et al
    Ovarian cancer risk factors by tumor aggressiveness: an analysis from the Ovarian Cancer Cohort Consortium.
    Int J Cancer. 2018 Dec 18. doi: 10.1002/ijc.32075.
    PubMed     Abstract available


  102. HAMERS FF, Assogba FAG, Rogel A
    Implementation and organization of cancer screening in France.
    Int J Cancer. 2018;143:3281.
    PubMed    


  103. ANDREASSEN T, Hansen BT, Engesaeter B, Hashim D, et al
    Psychological Effect of Cervical Cancer Screening When Changing Primary Screening Method From Cytology to hrHPV testing.
    Int J Cancer. 2018 Dec 14. doi: 10.1002/ijc.32067.
    PubMed     Abstract available


  104. SULTANA F, Winch K, Saville M, Brotherton JM, et al
    Is the positive predictive value of high-grade cytology in predicting high-grade cervical disease falling due to HPV vaccination?
    Int J Cancer. 2018 Dec 10. doi: 10.1002/ijc.32050.
    PubMed     Abstract available


  105. RADER JS, Tsaih SW, Fullin D, Murray MW, et al
    Genetic variations in human papillomavirus and cervical cancer outcomes.
    Int J Cancer. 2018 Dec 4. doi: 10.1002/ijc.32038.
    PubMed     Abstract available


  106. HALEC G, Scott ME, Farhat S, Darragh TM, et al
    Toll-like receptors: Important immune checkpoints in the regression of cervical intra-epithelial neoplasia 2.
    Int J Cancer. 2018;143:2884-2891.
    PubMed     Abstract available


    November 2018
  107. KIM S, Wang M, Tyrer JP, Jensen A, et al
    A Comprehensive Gene-Environment Interaction Analysis in Ovarian Cancer using Genome-wide Significant Common Variants.
    Int J Cancer. 2018 Nov 29. doi: 10.1002/ijc.32029.
    PubMed     Abstract available


  108. UTADA M, Chernyavskiy P, Lee WJ, Franceschi S, et al
    Increasing risk of uterine cervical cancer among young Japanese women: Comparison of incidence trends in Japan, South Korea and Japanese-Americans between 1985 and 2012.
    Int J Cancer. 2018 Nov 25. doi: 10.1002/ijc.32014.
    PubMed     Abstract available


  109. POLMAN NJ, Veldhuijzen NJ, Heideman DAM, Snijders PJF, et al
    Management of HPV-Positive Women in Cervical Screening Using Results from Two Consecutive Screening Rounds.
    Int J Cancer. 2018 Nov 22. doi: 10.1002/ijc.32004.
    PubMed     Abstract available


  110. SCHUBERT S, van Luttikhuizen JL, Auber B, Schmidt G, et al
    The identification of pathogenic variants in BRCA1/2 negative, high risk, hereditary breast and/or ovarian cancer patients: high frequency of FANCM pathogenic variants.
    Int J Cancer. 2018 Nov 13. doi: 10.1002/ijc.31992.
    PubMed     Abstract available


  111. RATAJ O, Haedicke-Jarboui J, Stubenrauch F, Iftner T, et al
    Brd4 inhibition suppresses HPV16 E6 expression and enhances chemoresponse: A potential new target in cervical cancer therapy.
    Int J Cancer. 2018 Nov 13. doi: 10.1002/ijc.31986.
    PubMed     Abstract available


  112. COOK DA, Krajden M, Brentnall AR, Gondara L, et al
    Evaluation of a validated methylation triage signature for human papillomavirus positive women in the HPV FOCAL cervical cancer screening trial.
    Int J Cancer. 2018 Nov 9. doi: 10.1002/ijc.31976.
    PubMed     Abstract available


  113. ISIDEAN SD, Wang Y, Mayrand MH, Ratnam S, et al
    Assessing the Time Dependence of Prognostic Values of Cytology and Human Papillomavirus Testing in Cervical Cancer Screening.
    Int J Cancer. 2018 Nov 9. doi: 10.1002/ijc.31970.
    PubMed     Abstract available


  114. RAGLAN O, Kalliala I, Markozannes G, Cividini S, et al
    Risk Factors for Endometrial Cancer: An umbrella review of the literature.
    Int J Cancer. 2018 Nov 2. doi: 10.1002/ijc.31961.
    PubMed     Abstract available


  115. PIMENOFF VN, Tous S, Benavente Y, Alemany L, et al
    Distinct geographic clustering of oncogenic human papillomaviruses multiple infections in cervical cancers: results from a worldwide cross-sectional study.
    Int J Cancer. 2018 Nov 2. doi: 10.1002/ijc.31964.
    PubMed     Abstract available


    October 2018
  116. KAMINENI A, Tiro JA, Beaber EF, Silverberg MJ, et al
    Cervical Cancer Screening Research in the PROSPR I Consortium: Rationale, Methods, and Baseline Findings from a U.S. Cohort.
    Int J Cancer. 2018 Oct 24. doi: 10.1002/ijc.31940.
    PubMed     Abstract available


  117. MACKINTOSH ML, Derbyshire AE, McVey RJ, Bolton J, et al
    The impact of obesity and bariatric surgery on circulating and tissue biomarkers of endometrial cancer risk.
    Int J Cancer. 2018 Oct 5. doi: 10.1002/ijc.31913.
    PubMed     Abstract available


    September 2018
  118. ELANDS RJ, Offermans NS, Simons CC, Schouten LJ, et al
    Associations of adult-attained height and early life energy restriction with postmenopausal breast cancer risk according to estrogen and progesterone receptor status.
    Int J Cancer. 2018 Sep 25. doi: 10.1002/ijc.31890.
    PubMed     Abstract available


  119. SAND FL, Munk C, Frederiksen K, Junge J, et al
    Risk of CIN3 or worse with persistence of 13 individual oncogenic HPV types.
    Int J Cancer. 2018 Sep 24. doi: 10.1002/ijc.31883.
    PubMed     Abstract available


  120. LIU Z, Zhang S, Hou F, Zhang C, et al
    Inhibition of Ca(2+) -activated chloride channel ANO1 suppresses ovarian cancer through inactivating PI3K/Akt signaling.
    Int J Cancer. 2018 Sep 22. doi: 10.1002/ijc.31887.
    PubMed     Abstract available


  121. TSANG SH, Peisch SF, Rowan B, Markt SC, et al
    Association between Trichomonas vaginalis and prostate cancer mortality.
    Int J Cancer. 2018 Sep 22. doi: 10.1002/ijc.31885.
    PubMed     Abstract available


  122. WANG Q, Song R, Zhao C, Liu H, et al
    HPV16 E6 promotes cervical cancer cell migration and invasion by downregulation of NHERF1.
    Int J Cancer. 2018 Sep 19. doi: 10.1002/ijc.31876.
    PubMed     Abstract available


  123. MONDAL S, Roy D, Sarkar Bhattacharya S, Jin L, et al
    Therapeutic targeting of PFKFB3 with a novel glycolytic inhibitor PFK158 promotes lipophagy and chemosensitivity in gynecologic cancers.
    Int J Cancer. 2018 Sep 18. doi: 10.1002/ijc.31868.
    PubMed     Abstract available


  124. KOMEMI O, Epstein Shochet G, Pomeranz M, Fishman A, et al
    Placenta-conditioned extracellular matrix (ECM) activates breast cancer cell survival mechanisms: A key for future distant metastases.
    Int J Cancer. 2018 Sep 8. doi: 10.1002/ijc.31861.
    PubMed     Abstract available


  125. SNOEK BC, Verlaat W, Babion I, Novianti PW, et al
    Genome-wide microRNA analysis of HPV-positive self-samples yields novel triage markers for early detection of cervical cancer.
    Int J Cancer. 2018 Sep 7. doi: 10.1002/ijc.31855.
    PubMed     Abstract available


  126. FALK RT, Manson JE, Barnabei VM, Anderson GL, et al
    Estrogen metabolism in menopausal hormone users in the Women's Health Initiative Observational Study: Does it differ between estrogen plus progestin and estrogen alone?
    Int J Cancer. 2018 Sep 5. doi: 10.1002/ijc.31851.
    PubMed     Abstract available


  127. LI J, Wen WX, Eklund M, Kvist A, et al
    Prevalence of BRCA1 and BRCA2 pathogenic variants in a large, unselected breast cancer cohort.
    Int J Cancer. 2018 Sep 2. doi: 10.1002/ijc.31841.
    PubMed     Abstract available


  128. BAUSSANO I, Lazzarato F, Ronco G, Franceschi S, et al
    Impacts of human papillomavirus vaccination for different populations: A modeling study.
    Int J Cancer. 2018;143:1086-1092.
    PubMed     Abstract available


    August 2018
  129. ZHANG C, Wang X, Anaya Y, Parodi L, et al
    Distinct Molecular Pathways in Ovarian Endometrioid Adenocarcinoma with Concurrent Endometriosis.
    Int J Cancer. 2018 Aug 28. doi: 10.1002/ijc.31768.
    PubMed     Abstract available


  130. OSTERMAN AL, Winer RL, Gottlieb GS, Sy MP, et al
    Female genital mutilation and non-invasive cervical abnormalities and invasive cervical cancer in Senegal, West Africa: A retrospective study.
    Int J Cancer. 2018 Aug 24. doi: 10.1002/ijc.31829.
    PubMed     Abstract available


  131. JOSHI S, Muwonge R, Kulkarni V, Deodhar K, et al
    Incidence of cervical intraepithelial neoplasia in women infected with human immunodeficiency virus (HIV) with no evidence of disease at baseline: results of a prospective cohort study with up to 6.4 years of follow-up from India.
    Int J Cancer. 2018 Aug 22. doi: 10.1002/ijc.31826.
    PubMed     Abstract available


  132. CAMPOS NG, Tsu V, Jeronimo J, Regan C, et al
    Health impact of delayed implementation of cervical cancer screening programs in India: A modelling analysis.
    Int J Cancer. 2018 Aug 21. doi: 10.1002/ijc.31823.
    PubMed     Abstract available


  133. JIN C, Liu Z, Li Y, Bu H, et al
    PCNA-associated factor P15(PAF) , targeted by FOXM1, predicts poor prognosis in high-grade serous ovarian cancer patients.
    Int J Cancer. 2018 Aug 21. doi: 10.1002/ijc.31800.
    PubMed     Abstract available


  134. BUCCHI L, Baldacchini F, Mancini S, Ravaioli A, et al
    Estimating the impact of an organised screening programme on cervical cancer incidence: a 26-year study from northern Italy.
    Int J Cancer. 2018 Aug 18. doi: 10.1002/ijc.31806.
    PubMed     Abstract available


  135. LU X, Li Y, Xia B, Bai Y, et al
    Selection of small plasma peptides for the auxiliary diagnosis and prognosis of epithelial ovarian cancer by using UPLC/MS-based non-targeted and targeted analyses.
    Int J Cancer. 2018 Aug 16. doi: 10.1002/ijc.31807.
    PubMed     Abstract available


  136. KIVES Z, Juhasz K, Csakvari T, Agoston I, et al
    Cancer screening policy in Hungary.
    Int J Cancer. 2018;143:1003-1004.
    PubMed    


  137. NEFF R, Rush CM, Smith B, Backes FJ, et al
    Functional characterization of recurrent FOXA2 mutations seen in endometrial cancers.
    Int J Cancer. 2018 Aug 9. doi: 10.1002/ijc.31784.
    PubMed     Abstract available


  138. HE W, Hou M, Zhang H, Zeng C, et al
    Clinical significance of circulating tumor cells in predicting disease progression and chemotherapy resistance in patients with gestational choriocarcinoma.
    Int J Cancer. 2018 Aug 2. doi: 10.1002/ijc.31742.
    PubMed     Abstract available


  139. CHUANG SC, Lin CH, Lu YS, Hsiung CA, et al
    Association of pregnancy and mortality in women diagnosed with breast cancer: A nationwide population based study in Taiwan.
    Int J Cancer. 2018 Aug 2. doi: 10.1002/ijc.31777.
    PubMed     Abstract available


  140. GOMIH A, Smith JS, North KE, Hudgens MG, et al
    DNA methylation of imprinted gene control regions in the regression of low-grade cervical lesions.
    Int J Cancer. 2018;143:552-560.
    PubMed     Abstract available


    July 2018
  141. CHEN HJ, Huang RL, Liew PL, Su PH, et al
    GATA3 as a master regulator and therapeutic target in ovarian high-grade serous carcinoma stem cells.
    Int J Cancer. 2018 Jul 14. doi: 10.1002/ijc.31750.
    PubMed     Abstract available


  142. AKINWUNMI B, Vitonis AF, Titus L, Terry KL, et al
    Statin Therapy and Association with Ovarian Cancer risk in the New England Case Control (NEC) Study.
    Int J Cancer. 2018 Jul 14. doi: 10.1002/ijc.31758.
    PubMed     Abstract available


  143. TESCH H, Stoetzer O, Decker T, Kurbacher CM, et al
    Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: Results of the single-arm, phase IIIB 4EVER trial
    Int J Cancer. 2018 Jul 11. doi: 10.1002/ijc.31738.
    PubMed     Abstract available


  144. CLENDENEN TV, Dorgan J, Zeleniuch-Jacquotte A
    Reply to: Anti-Mullerian hormone and breast cancer risk- is the correlation possibly associated with the PCOS?
    Int J Cancer. 2018 Jul 11. doi: 10.1002/ijc.31728.
    PubMed    


  145. BLUMENFELD Z
    Anti-Mullerian hormone and breast cancer risk- is the correlation possibly associated with the PCOS?
    Int J Cancer. 2018 Jul 10. doi: 10.1002/ijc.31732.
    PubMed    


  146. SAAVALAINEN L, Lassus H, But A, Tiitinen A, et al
    A nationwide cohort study on the risk of non-gynaecological cancers in women with surgically verified endometriosis.
    Int J Cancer. 2018 Jul 7. doi: 10.1002/ijc.31721.
    PubMed     Abstract available


  147. AUSTRIA T, Marion C, Yu V, Widschwendter M, et al
    Mechanism of cytokinesis failure in ovarian cystadenomas with defective brca1 and p53 pathways.
    Int J Cancer. 2018 Jul 6. doi: 10.1002/ijc.31659.
    PubMed     Abstract available


  148. CERVENKA I, Mahamat-Saleh Y, Savoye I, Dartois L, et al
    Oral contraceptive use and cutaneous melanoma risk: A french prospective cohort study.
    Int J Cancer. 2018 Jul 6. doi: 10.1002/ijc.31644.
    PubMed     Abstract available


  149. JASKULSKI S, Jung AY, Behrens S, Johnson T, et al
    Circulating enterolactone concentrations and prognosis of postmenopausal breast cancer: Assessment of mediation by inflammatory markers.
    Int J Cancer. 2018 Jul 4. doi: 10.1002/ijc.31647.
    PubMed     Abstract available


    June 2018
  150. GUSTAVSSON I, Aarnio R, Berggrund M, Hedlund-Lindberg J, et al
    Randomized study of HPV prevalence and detection of CIN2+ in vaginal self-sampling compared to cervical specimens collected by medical personnel.
    Int J Cancer. 2018 Jun 26. doi: 10.1002/ijc.31637.
    PubMed     Abstract available


  151. REZHAKE R, Hu SY, Zhao S, Xu XQ, et al
    Eight-type human papillomavirus E6/E7 oncoprotein detection as a novel and promising triage strategy for managing HPV-positive women.
    Int J Cancer. 2018 Jun 26. doi: 10.1002/ijc.31633.
    PubMed     Abstract available


  152. DYG SPERLING C, Verdoodt F, Kjaer Hansen M, Dehlendorff C, et al
    Statin use and mortality among endometrial cancer patients: a Danish nationwide cohort study.
    Int J Cancer. 2018 Jun 19. doi: 10.1002/ijc.31625.
    PubMed     Abstract available


  153. KO KP, Kim SJ, Huzarski T, Gronwald J, et al
    The association between smoking and cancer incidence in BRCA1 and BRCA2 mutation carriers.
    Int J Cancer. 2018;142:2263-2272.
    PubMed     Abstract available


    May 2018
  154. OLORUNFEMI G, Ndlovu N, Masukume G, Chikandiwa A, et al
    Temporal trends in the epidemiology of cervical cancer in South Africa (1994-2012).
    Int J Cancer. 2018 May 22. doi: 10.1002/ijc.31610.
    PubMed     Abstract available


  155. TROISI R, Gulbech Ording A, Grotmol T, Glimelius I, et al
    Pregnancy Complications and Subsequent Breast Cancer Risk in the Mother: A Nordic population-based case-control study.
    Int J Cancer. 2018 May 11. doi: 10.1002/ijc.31600.
    PubMed     Abstract available


  156. BIZZARO F, Falcetta F, D'Agostini E, Decio A, et al
    Tumor progression and metastatic dissemination in ovarian cancer after dose-dense or conventional paclitaxel and cisplatin plus bevacizumab.
    Int J Cancer. 2018 May 11. doi: 10.1002/ijc.31596.
    PubMed     Abstract available


  157. SKOLD C, Bjorge T, Ekbom A, Engeland A, et al
    Preterm delivery is associated with an increased risk of epithelial ovarian cancer among parous women.
    Int J Cancer. 2018 May 8. doi: 10.1002/ijc.31581.
    PubMed     Abstract available


  158. HUANG RL, Chen HJ, Chen LY, Chao TK, et al
    Epigenetic loss of heparan sulfate 3-O-sulfation sensitizes ovarian carcinoma to oncogenic signals and predicts prognosis.
    Int J Cancer. 2018 May 7. doi: 10.1002/ijc.31580.
    PubMed     Abstract available


    April 2018
  159. CHAN KK, Wong OG, Wong ES, Chan KK, et al
    Impact of iASPP on chemoresistance through PLK1 and autophagy in ovarian clear cell carcinoma.
    Int J Cancer. 2018 Apr 16. doi: 10.1002/ijc.31535.
    PubMed     Abstract available


  160. DE STROOPER LMA, Berkhof J, Steenbergen RDM, Lissenberg-Witte BI, et al
    Cervical cancer risk in HPV-positive women after a negative FAM19A4/mir124-2 methylation test: A post hoc analysis in the POBASCAM trial with 14 year follow-up.
    Int J Cancer. 2018 Apr 16. doi: 10.1002/ijc.31539.
    PubMed     Abstract available


  161. CHAN KK, Wong OG, Wong ES, Chan KK, et al
    Impact of iASPP on chemoresistance through PLK1 and autophagy in ovarian clear cell carcinoma.
    Int J Cancer. 2018 Apr 12. doi: 10.1002/ijc.31427.
    PubMed     Abstract available


  162. AGOSTINI A, Brunetti M, Davidson B, Trope CG, et al
    Identification of novel cyclin gene fusion transcripts in endometrioid ovarian carcinomas.
    Int J Cancer. 2018 Apr 6. doi: 10.1002/ijc.31418.
    PubMed     Abstract available


  163. CUBURU N, Khan S, Thompson CD, Kim R, et al
    Adenovirus vector-based prime-boost vaccination via heterologous routes induces cervicovaginal CD8(+) T cell responses against HPV16 oncoproteins.
    Int J Cancer. 2018;142:1467-1479.
    PubMed     Abstract available


    March 2018
  164. ANNUNZIATA C, Pezzuto F, Greggi S, Ionna F, et al
    Distinct profiles of TERT promoter mutations and telomerase expression in head and neck cancer and cervical carcinoma.
    Int J Cancer. 2018 Mar 31. doi: 10.1002/ijc.31412.
    PubMed     Abstract available


  165. GUINTER MA, McLain AC, Merchant AT, Sandler DP, et al
    A dietary pattern based on estrogen metabolism is associated with breast cancer risk in a prospective cohort of postmenopausal women.
    Int J Cancer. 2018 Mar 25. doi: 10.1002/ijc.31387.
    PubMed     Abstract available


  166. PAPAEVANGELOU E, Almeida GS, Box C, deSouza NM, et al
    The effect of FASN inhibition on the growth and metabolism of a cisplatin-resistant ovarian carcinoma model.
    Int J Cancer. 2018 Mar 23. doi: 10.1002/ijc.31392.
    PubMed     Abstract available


  167. KELLEN E, Benoy I, Vanden Broeck D, Martens P, et al
    A randomized, controlled trial of two strategies of offering the home-based HPV self-sampling test to non- participants in the Flemish cervical cancer screening program.
    Int J Cancer. 2018 Mar 23. doi: 10.1002/ijc.31391.
    PubMed     Abstract available


  168. GUO W, Key TJ, Reeves GK
    Adiposity and breast cancer risk in postmenopausal women: Results from the UK Biobank prospective cohort.
    Int J Cancer. 2018 Mar 23. doi: 10.1002/ijc.31394.
    PubMed     Abstract available


  169. VINTERMYR OK, Andersland MS, Bjorge T, Skar R, et al
    Human papillomavirus type specific risk of progression and remission during long term follow-up of equivocal and low grade HPV-positive cervical smears.
    Int J Cancer. 2018 Mar 23. doi: 10.1002/ijc.31390.
    PubMed     Abstract available


  170. BROOKS JD, Sung JS, Pike MC, Orlow I, et al
    MRI background parenchymal enhancement, breast density and serum hormones in postmenopausal women.
    Int J Cancer. 2018 Mar 9. doi: 10.1002/ijc.31370.
    PubMed     Abstract available


  171. YU L, Jiang M, Qu P, Wu Z, et al
    Clinical Evaluation of Human Papillomavirus 16/18 Oncoprotein Test for Cervical Cancer Screening and HPV Positive Women Triage.
    Int J Cancer. 2018 Mar 9. doi: 10.1002/ijc.31368.
    PubMed     Abstract available


  172. WRIGHT LB, Schoemaker MJ, Jones ME, Ashworth A, et al
    Breast cancer risk in relation to history of preeclampsia and hyperemesis gravidarum: Prospective analysis in the Generations Study.
    Int J Cancer. 2018 Mar 8. doi: 10.1002/ijc.31364.
    PubMed     Abstract available


  173. LEHTINEN M, Soderlund-Strand A, Vanska S, Luostarinen T, et al
    Impact of gender-neutral or girls-only vaccination against human papillomavirus-Results of a community-randomized clinical trial (I).
    Int J Cancer. 2018;142:949-958.
    PubMed     Abstract available


    February 2018
  174. KABAT GC, Kim MY, Stefanick M, Ho GYF, et al
    Metabolic obesity phenotypes and risk of colorectal cancer in postmenopausal women.
    Int J Cancer. 2018 Feb 27. doi: 10.1002/ijc.31345.
    PubMed     Abstract available


  175. KAAKS R, Fortner RT, Husing A, Barrdahl M, et al
    Tumor-associated auto-antibodies as early detection markers for ovarian cancer? A prospective evaluation.
    Int J Cancer. 2018 Feb 22. doi: 10.1002/ijc.31335.
    PubMed     Abstract available


  176. DEL MISTRO A, Adcock R, Carozzi F, Gillio-Tos A, et al
    HPV genotyping for the cross-sectional and longitudinal probability of developing CIN2.
    Int J Cancer. 2018 Feb 17. doi: 10.1002/ijc.31326.
    PubMed     Abstract available


  177. LIEW PL, Huang RL, Weng YC, Fang CL, et al
    Distinct methylation profile of mucinous ovarian carcinoma reveals susceptibility to proteasome inhibitors.
    Int J Cancer. 2018 Feb 16. doi: 10.1002/ijc.31324.
    PubMed     Abstract available


  178. RIETBERGEN MM, van Bokhoven AAJD, Lissenberg-Witte BI, Heideman DAM, et al
    Epidemiologic associations of HPV-positive oropharyngeal cancer and (pre)cancerous cervical lesions.
    Int J Cancer. 2018 Feb 14. doi: 10.1002/ijc.31315.
    PubMed     Abstract available


  179. LECAVALIER-BARSOUM M, Chaudary N, Han K, Koritzinsky M, et al
    Targeting the CXCL12/CXCR4 Pathway and Myeloid Cells to Improve Radiation Treatment of Locally Advanced Cervical Cancer.
    Int J Cancer. 2018 Feb 8. doi: 10.1002/ijc.31297.
    PubMed     Abstract available


  180. FALCONER H, Yin L, Altman D
    Association between tubal ligation and endometrial cancer risk: A Swedish population-based cohort study.
    Int J Cancer. 2018 Feb 1. doi: 10.1002/ijc.31287.
    PubMed     Abstract available


    January 2018
  181. YANG X, Wang N, Chen J
    Subsequent primary malignancies after endometrial cancer diagnosed in American cancer registries.
    Int J Cancer. 2018 Jan 31. doi: 10.1002/ijc.31284.
    PubMed    


  182. ZHENG J, Merchant AT, Wirth MD, Zhang J, et al
    Inflammatory potential of diet and risk of pancreatic cancer in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial.
    Int J Cancer. 2018 Jan 22. doi: 10.1002/ijc.31271.
    PubMed     Abstract available


  183. LOKKEGAARD ECL, Morch LS
    Tibolone and risk of gynecological hormone sensitive cancer.
    Int J Cancer. 2018 Jan 19. doi: 10.1002/ijc.31267.
    PubMed     Abstract available


  184. DE KOK IMCM, Korfage IJ, van den Hout WB, Helmerhorst TJM, et al
    Quality of life assumptions determine which cervical cancer screening strategies are cost-effective.
    Int J Cancer. 2018 Jan 19. doi: 10.1002/ijc.31265.
    PubMed     Abstract available


  185. BUSUND M, Bugge NS, Braaten T, Waaseth M, et al
    Progestin-Only and Combined Oral Contraceptives and Receptor-Defined Premenopausal Breast Cancer Risk: The Norwegian Women and Cancer Study.
    Int J Cancer. 2018 Jan 19. doi: 10.1002/ijc.31266.
    PubMed     Abstract available


  186. CUSCHIERI K, Ronco G, Lorincz A, Smith L, et al
    Eurogin Roadmap 2017: Triage strategies for the management of HPV-positive women in cervical screening programmes.
    Int J Cancer. 2018 Jan 17. doi: 10.1002/ijc.31261.
    PubMed     Abstract available


  187. BASU P, Ponti A, Anttila A, Ronco G, et al
    Status of implementation and organization of cancer screening in The European Union Member States-Summary results from the second European screening report.
    Int J Cancer. 2018;142:44-56.
    PubMed     Abstract available


    December 2017
  188. LUOSTARINEN T, Apter D, Dillner J, Eriksson T, et al
    Vaccination protects against invasive HPV-associated cancers.
    Int J Cancer. 2017 Dec 26. doi: 10.1002/ijc.31231.
    PubMed    


  189. GULTEKIN M, Zayifoglu Karaca M, Kucukyildiz I, Dundar S, et al
    Initial results of population based cervical cancer screening program using hpv testing in one million turkish women.
    Int J Cancer. 2017 Dec 13. doi: 10.1002/ijc.31212.
    PubMed     Abstract available


  190. KHAIRALLAH AS, Genestie C, Auguste A, Leary A, et al
    Impact of neoadjuvant chemotherapy on the immune microenvironment in advanced epithelial ovarian cancer: Prognostic and therapeutic implications.
    Int J Cancer. 2017 Dec 8. doi: 10.1002/ijc.31200.
    PubMed    


  191. SAND FL, Frederiksen K, Munk C, Jensen SM, et al
    Long-Term Risk of Cervical Cancer Following Conization of Cervical Intraepithelial Neoplasia Grade 3 - A Danish Nationwide Cohort Study.
    Int J Cancer. 2017 Dec 8. doi: 10.1002/ijc.31202.
    PubMed     Abstract available


  192. KANG YJ, Smith M, Barlow E, Coffey K, et al
    Vulvar cancer in high-income countries: Increasing burden of disease.
    Int J Cancer. 2017;141:2174-2186.
    PubMed     Abstract available


  193. REIMER D, Boesch M, Wolf D, Marth C, et al
    Truncated isoform Vav3.1 is highly expressed in ovarian cancer stem cells and clinically relevant in predicting prognosis and platinum-response.
    Int J Cancer. 2017 Dec 1. doi: 10.1002/ijc.31186.
    PubMed     Abstract available


    November 2017
  194. JOHANSSON ALV, Andersson TM, Hsieh CC, Jirstrom K, et al
    Tumor characteristics and prognosis in women with pregnancy-associated breast cancer.
    Int J Cancer. 2017 Nov 23. doi: 10.1002/ijc.31174.
    PubMed     Abstract available


  195. FORTNER RT, Schock H, Le Cornet C, Husing A, et al
    Ovarian Cancer Early Detection by Circulating CA125 in the context of Anti-CA125 Autoantibody Levels: Results from the EPIC cohort.
    Int J Cancer. 2017 Nov 21. doi: 10.1002/ijc.31164.
    PubMed     Abstract available


  196. KIM J, Field A, Schultz KAP, Hill DA, et al
    The prevalence of DICER1 pathogenic variation in population databases.
    Int J Cancer. 2017;141:2030-2036.
    PubMed     Abstract available


  197. REGER MK, Zollinger TW, Liu Z, Jones JF, et al
    Dietary intake of isoflavones and coumestrol and the risk of prostate cancer in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.
    Int J Cancer. 2017 Nov 8. doi: 10.1002/ijc.31095.
    PubMed     Abstract available


  198. RASMUSSEN CL, Sand FL, Hoffmann Frederiksen M, Andersen KK, et al
    Does HPV status influence survival after vulvar cancer?
    Int J Cancer. 2017 Nov 1. doi: 10.1002/ijc.31139.
    PubMed     Abstract available


    October 2017
  199. CUPPENS T, Moisse M, Depreeuw J, Annibali D, et al
    Integrated genome analysis of uterine leiomyosarcoma to identify novel driver genes and targetable pathways.
    Int J Cancer. 2017 Oct 24. doi: 10.1002/ijc.31129.
    PubMed     Abstract available


  200. FELIX AS, Brasky TM, Cohn DE, Mutch DG, et al
    Endometrial carcinoma recurrence according to race and ethnicity: An NRG Oncology/Gynecologic Oncology Group 210 Study.
    Int J Cancer. 2017 Oct 24. doi: 10.1002/ijc.31127.
    PubMed     Abstract available


  201. MATSUZAKI S, Serada S, Hiramatsu K, Nojima S, et al
    Anti-glypican-1 antibody-drug conjugate exhibits potent preclinical antitumor activity against glypican-1 positive uterine cervical cancer.
    Int J Cancer. 2017 Oct 21. doi: 10.1002/ijc.31124.
    PubMed     Abstract available


  202. LANDY R, Windridge P, Gillman MS, Sasieni PD, et al
    What cervical screening is appropriate for women who have been vaccinated against high risk HPV? A simulation study.
    Int J Cancer. 2017 Oct 11. doi: 10.1002/ijc.31094.
    PubMed     Abstract available


  203. MATSUO K, Shimada M, Yamaguchi S, Kanao H, et al
    Identifying a candidate population for ovarian conservation in young women with clinical stage IB-IIB cervical cancer.
    Int J Cancer. 2017 Oct 4. doi: 10.1002/ijc.31084.
    PubMed     Abstract available


  204. PAN R, Zhu M, Yu C, Lv J, et al
    Cancer incidence and mortality: A cohort study in China, 2008-2013.
    Int J Cancer. 2017;141:1315-1323.
    PubMed     Abstract available


    September 2017
  205. VIDART D'EGURBIDE BAGAZGOITIA , Bailey HD, Orsi L, Lacour B, et al
    Maternal residential pesticide use during pregnancy and risk of malignant childhood brain tumors: A pooled analysis of the ESCALE and ESTELLE studies (SFCE).
    Int J Cancer. 2017 Sep 26. doi: 10.1002/ijc.31073.
    PubMed     Abstract available


  206. GAITSKELL K, Green J, Pirie K, Barnes I, et al
    Histological subtypes of ovarian cancer associated with parity and breastfeeding in the prospective Million Women Study.
    Int J Cancer. 2017 Sep 20. doi: 10.1002/ijc.31063.
    PubMed     Abstract available


  207. RICE MS, Rist PM, Winter AC, Kurth T, et al
    Migraine and invasive epithelial ovarian cancer risk in the Nurses' Health Study II and the Women's Health Study.
    Int J Cancer. 2017 Sep 20. doi: 10.1002/ijc.31062.
    PubMed     Abstract available


  208. JUNG S, Allen N, Arslan AA, Baglietto L, et al
    Anti-Mullerian Hormone and risk of ovarian cancer in nine cohorts.
    Int J Cancer. 2017 Sep 18. doi: 10.1002/ijc.31058.
    PubMed     Abstract available


  209. QUIST AJL, Inoue-Choi M, Weyer PJ, Anderson KE, et al
    Ingested nitrate and nitrite, disinfection by-products, and pancreatic cancer risk in postmenopausal women.
    Int J Cancer. 2017 Sep 16. doi: 10.1002/ijc.31055.
    PubMed     Abstract available


  210. FABER MT, Sand FL, Albieri V, Norrild B, et al
    Prevalence and type distribution of human papillomavirus in squamous cell carcinoma and intraepithelial neoplasia of the vulva.
    Int J Cancer. 2017;141:1161-1169.
    PubMed     Abstract available


  211. ZHANG Q, Dong L, Hu S, Feng R, et al
    Risk stratification and long-term risk prediction of E6 oncoprotein in a prospective screening cohort in China.
    Int J Cancer. 2017;141:1110-1119.
    PubMed     Abstract available


    August 2017
  212. RAKISLOVA N, Clavero O, Alemany L, Saco A, et al
    "Histological characteristics of HPV-associated and -independent squamous cell carcinomas of the vulva: A study of 1594 cases".
    Int J Cancer. 2017 Aug 17. doi: 10.1002/ijc.31006.
    PubMed     Abstract available


  213. CLARKE MA, Luhn P, Gage JC, Bodelon C, et al
    Discovery and validation of candidate host DNA methylation markers for detection of cervical precancer and cancer.
    Int J Cancer. 2017;141:701-710.
    PubMed     Abstract available


  214. CHASIMPHA SJD, Parkin DM, Masamba L, Dzamalala CP, et al
    Three-year cancer incidence in Blantyre, Malawi (2008-2010).
    Int J Cancer. 2017;141:694-700.
    PubMed     Abstract available


    July 2017
  215. KHAN S, Oosterhuis K, Wunderlich K, Bunnik EM, et al
    Development of a replication-deficient adenoviral vector-based vaccine candidate for the interception of HPV16- and HPV18-induced infections and disease.
    Int J Cancer. 2017;141:393-404.
    PubMed     Abstract available


  216. GU F, Zhang H, Hyland PL, Berndt S, et al
    Inherited variation in circadian rhythm genes and risks of prostate cancer and three other cancer sites in combined cancer consortia.
    Int J Cancer. 2017 Jul 12. doi: 10.1002/ijc.30883.
    PubMed     Abstract available


  217. VELDHUIJZEN NJ, Polman NJ, Snijders PJF, Meijer CJLM, et al
    Stratifying HPV-positive women for CIN3+ risk after one and two rounds of HPV-based screening.
    Int J Cancer. 2017 Jul 3. doi: 10.1002/ijc.30865.
    PubMed     Abstract available


    June 2017
  218. MATSUMOTO K, Yaegashi N, Iwata T, Yamamoto K, et al
    Early impact of the Japanese immunization program implemented before the HPV vaccination crisis.
    Int J Cancer. 2017 Jun 28. doi: 10.1002/ijc.30855.
    PubMed    


    May 2017
  219. AGORASTOS T, Chatzistamatiou K, Moysiadis T, Kaufmann AM, et al
    Human papillomavirus E7 protein detection as a method of triage to colposcopy of HPV positive women, in comparison to genotyping and cytology. Final results of the PIPAVIR study.
    Int J Cancer. 2017 May 3. doi: 10.1002/ijc.30761.
    PubMed    


  220. SHEN C, Liu Y, Shi S, Zhang R, et al
    Long-distance interaction of the integrated HPV fragment with MYC gene and 8q24.22 region up-regulating the allele-specific MYC expression in HeLa cells.
    Int J Cancer. 2017 May 3. doi: 10.1002/ijc.30763.
    PubMed     Abstract available


    April 2017
  221. DE MARTEL C, Plummer M, Vignat J, Franceschi S, et al
    Worldwide burden of cancer attributable to HPV by site, country and HPV type.
    Int J Cancer. 2017 Apr 1. doi: 10.1002/ijc.30716.
    PubMed     Abstract available


    January 2017
  222. MANCINI S, Ravaioli A, Giuliani O, Vattiato R, et al
    Incidence and survival trends of cervical adenocarcinoma in Italy: Cytology screening has become more effective in downstaging the disease but not in detecting its precursors.
    Int J Cancer. 2017;140:247-248.
    PubMed    


    December 2016
  223. BOGANI G, Chiappa V, Martinelli F, Raspagliesi F, et al
    Type-Specific HPV Infection Correlates with Risk of Recurrence of Vulvar Intraepithelial Neoplasia Usual Type.
    Int J Cancer. 2016 Dec 22. doi: 10.1002/ijc.30585.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Gynecology is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: